Trial Profile
An Open-Label, Baseline-Controlled, Long-term, Safety, Tolerability and Efficacy Study of Levodopa-Carbidopa Intestinal Gel (SLV187) in Levodopa-Responsive Subjects With Advanced Parkinson's Disease.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2013
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Abbott Laboratories; AbbVie
- 05 Oct 2010 New trial record